COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
29/09/2026
Company investments from the past five years, together with the forecast for 2026, are projected to reach EUR 500 million by year-end 2026, encompassing all expenditure on sustainability-related projects and health [...]
Ocugen to Participate in Upcoming October Investor and Industry Conferences
29/09/2026
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of [...]
PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
29/09/2026
Pivotal SkinTE® data in non-healing Wagner Grade 1 diabetic foot ulcers to be presented by Study Chair Robert S. Kirsner, MD, PhD, on October 16 SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) -- PolarityBio® , a late- [...]
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
29/09/2026
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and [...]
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
29/09/2026
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in 2L/3L advanced or metastatic non-squamous NSCLC without actionable genomic [...]
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
29/09/2026
OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing [...]
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
29/09/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“ CDT ” or the “ Company ”) today notes the announcement from Sarborg Limited regarding the filing of new [...]
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
29/09/2026
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, [...]
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
29/09/2026
Trilivy™ is designed to address the challenges of metabolic dysfunction Clients on Trilivy's Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed [...]
ABBYY Appoints Paula Sanders to Chief Customer Experience Officer, Providing Customers a Single, End-to-End Experience
29/09/2026
AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- ABBYY today announced the appointment of Paula Sanders to Chief Customer Experience Officer (CCXO) to provide customers a consistent, connected experience across every [...]
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
29/09/2026
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating [...]
GUERBET : Mise à disposition du Rapport Financier semestriel 2026
29/09/2026
Mise à disposition du Rapport Financier semestriel 2026 Villepinte, le 29 septembre 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale annonce ce jour [...]
Transactions in connection with share buy-back program
29/09/2026
Company announcement no. 37 - 26 29 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
29/09/2026
The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development The milestone [...]
Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD
29/09/2026
KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB), idiopathic pulmonary fibrosis (IPF) and cystic [...]
Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
29/09/2026
Co-led by new investor Mission BioCapital and existing investor Novo Holdings, with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family office, Innovestor Life [...]
Rapid Nutrition Reports Record Q3 Group Revenue Averaging $1 Million per Month, Up More Than 1,000% on FY2025 Monthly Average
29/09/2026
Third-quarter trading marks a key milestone in the execution of the Group’s accelerated growth strategy and positions Rapid Nutrition for a record second half LONDON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition [...]
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
29/09/2026
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the [...]
AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques
29/09/2026
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR SON PLAN DE DEVELOPPEMENT ET SON CALENDRIER FINANCIER À LA SUITE D'UNE INSPECTION PROMOTEUR DES BONNES PRATIQUES CLINIQUES Confirmation de la pertinance d’avoir, parmi [...]

Pages